IFP Advisors
SPRY icon

IFP Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

IFP Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$60 Buy
14
+3
+27% +$18 ﹤0.01% 5045
2026
Q2 		$88 Buy
+11
New +$95 ﹤0.01% 4972
2025
Q2 		– Hold
0
– – – 4045
2025
Q1 		– Hold
0
– – – 4213
2024
Q4 		– Hold
0
– – – 4527

Other funds holding SPRY

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
NFGCM
Norman Fields Gottscho Capital Management New York $329M AUM 22.06% 1-Year Est. Return
CX Institutional
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
BLC
Brown, Lisle/Cummings Providence, Rhode Island $453M AUM 20.23% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

IFP Advisors's SPRY Position: Q3 2026 in Review

IFP Advisors increased its ARS Pharmaceuticals (SPRY) stake by 27% in Q3 2026, buying an estimated $18 and bringing the position to 14 shares worth $60. The position accounts for ﹤0.01% of the portfolio, ranked #5045.

IFP Advisors first reported a position in SPRY in Q2 2026 and has held it in 2 quarters since. The position peaked at $88 in Q2 2026. 12 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • IFP Advisors held 14 shares of ARS Pharmaceuticals worth $60 as of Q3 2026.
  • IFP Advisors bought 3 ARS Pharmaceuticals shares in Q3 2026, an estimated $18.
  • ARS Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #5045 holding.
  • IFP Advisors first reported a position in ARS Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • IFP Advisors's ARS Pharmaceuticals position peaked at $88 in Q2 2026.
  • 12 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.